279 related articles for article (PubMed ID: 37298700)
1. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.
Iwanowski T; Kołkowski K; Nowicki RJ; Sokołowska-Wojdyło M
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298700
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
3. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
4. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of vitiligo.
Karagaiah P; Valle Y; Sigova J; Zerbinati N; Vojvodic P; Parsad D; Schwartz RA; Grabbe S; Goldust M; Lotti T
Expert Opin Emerg Drugs; 2020 Mar; 25(1):7-24. PubMed ID: 31958256
[No Abstract] [Full Text] [Related]
6. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.
Diotallevi F; Gioacchini H; De Simoni E; Marani A; Candelora M; Paolinelli M; Molinelli E; Offidani A; Simonetti O
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902341
[TBL] [Abstract][Full Text] [Related]
7. Topical ruxolitinib: A new treatment for vitiligo.
Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
[TBL] [Abstract][Full Text] [Related]
8. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.
Guttman-Yassky E; Del Duca E; Da Rosa JC; Bar J; Ezzedine K; Ye Z; He W; Hyde C; Hassan-Zahraee M; Yamaguchi Y; Peeva E
J Allergy Clin Immunol; 2024 Jan; 153(1):161-172.e8. PubMed ID: 37777018
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K; Peeva E; Yamaguchi Y; Cox LA; Banerjee A; Han G; Hamzavi I; Ganesan AK; Picardo M; Thaçi D; Harris JE; Bae JM; Tsukamoto K; Sinclair R; Pandya AG; Sloan A; Yu D; Gandhi K; Vincent MS; King B
J Am Acad Dermatol; 2023 Feb; 88(2):395-403. PubMed ID: 36370907
[TBL] [Abstract][Full Text] [Related]
10. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
11. Vitiligo: Pathogenesis and New and Emerging Treatments.
Perez-Bootello J; Cova-Martin R; Naharro-Rodriguez J; Segurado-Miravalles G
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139134
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
[TBL] [Abstract][Full Text] [Related]
13. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
Yousefian F; Yadlapati S; Browning JC
J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
[TBL] [Abstract][Full Text] [Related]
14. Biologic and targeted therapeutics in vitiligo.
Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
[TBL] [Abstract][Full Text] [Related]
15. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann MC; Haidari W; Feldman SR
J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
[TBL] [Abstract][Full Text] [Related]
16. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG; King BA
JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
[TBL] [Abstract][Full Text] [Related]
18. Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients.
Renert-Yuval Y; Ezzedine K; Grimes P; Rosmarin D; Eichenfield LF; Castelo-Soccio L; Huang V; Desai SR; Walsh S; Silverberg JI; Paller AS; Rodrigues M; Weingarten M; Narla S; Gardner J; Siegel M; Ibad S; Silverberg NB
JAMA Dermatol; 2024 Apr; 160(4):453-461. PubMed ID: 38477910
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors.
Cunningham KN; Rosmarin D
Am J Clin Dermatol; 2023 Mar; 24(2):165-186. PubMed ID: 36715849
[TBL] [Abstract][Full Text] [Related]
20. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]